51389-5 |
Views^W Tl-201 IV |
Find |
Breast |
Pt |
Doc |
NM |
|
ACTIVE |
NM Breast Views W Tl-201 IV |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
51389-5 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Brst Views W Tl-201 IV |
|
|
|
N |
|
201TI; Brst; Document; Films; Finding; Findings; Imaging; Point in time; Rad; RADIOLOGY; Random; Scan; Thallium 201; Thallous; T-I201; TL-201; View; VWS |
2.64 |
2.22 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier. |
0 |
5139-1 |
Echovirus 19 Ab |
Titr |
Ser |
Pt |
SemiQn |
Comp fix |
|
ACTIVE |
Echovirus 19 Ab [Titer] in Serum by Complement fixation |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
5139-1 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
ECV19 Ab Titr Ser CF |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CF; Comp fixation; Compfix; Complement fixation; Dilution factor; Dilution Factor (Titer); Echo; Echo virus; Echovirus type 19; ECV; ECV19; EV; ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
51390-3 |
Views AP & lateral |
Find |
Abdomen |
Pt |
Nar |
XR |
|
DEPRECATED |
Deprecated Abdomen X-ray AP & lateral |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
51390-3 |
|
XR |
|
|
Both |
|
|
|
0 |
Deprecated Abd XR AP+Lat |
|
|
|
N |
|
Abd; Abdo; Abdomen+; Abdominal; Anterio-Posterior; Anteroposterior; AP+Lat; Films; Finding; Findings; Imaging; Lat; Narrative; Plain Films; Point in time; Rad; RADIOLOGY; Random; Report; View; Views & AP KUB; Views (AP; Views AP KUB & lateral; Views AP+lateral; Views+AP; VWS; Xray; X-ray |
2.36 |
2.22 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
51391-1 |
Guidance for transjugular placement of transjugular intrahepatic portosystemic shunt |
Find |
Abdomen>Portal vein+Hepatic vein |
Pt |
Doc |
RF.angio |
|
ACTIVE |
RFA Guidance for placement of TIPS of Portal vein and Hepatic vein |
|
MIN |
DefinitionDescription |
|
|
|
CLINICAL HISTORY: GI BLEED REPORT: ADDITIONAL CLINICAL INFORMATION: BLEEDING, GASTRIC VARICES. NOT AMENABLE TO ENDOSCOPIC THERAPY. PATIENT HEMODYNAMICALLY UNSTABLE. TECHNIQUE: Written informed consent was obtained from the patient's family. The patient was placed supine. The right internal jugular vein was accessed with a 21 gauge need. A Kumpe catheter and hydrophilic guide were used to select the right hepatic vein. A 5 French balloon occlusion catheter was advanced to the terminates of the vein and the balloon inflated. C2 wedged hepatic venography was performed opacifying the right portal vein. The vein was accessed with a Colapinto needle. The needle was exchanged for a catheter. Through the 9 French sheath placed in the right atrium, dual pressures were obtained. The portal pressure was measured at 25 mmHg and the systemic pressure at 8 mmHg for a portal systemic gradient of 17 mmHg. Angiography was performed revealing three large caliber para-perigastric varices. Other smaller varices were identified. At this point, the intrahepatic tract was dilated to 6 mm and a 10 mm x 6 mm Prot'e9g'e9 stent deployed from the right portal vein toward the hepatic vein. The stent was short and a second 10 mm x 4 cm Prot'e9g'e9 stent placed to the hepatic vein. This was dilated to 9 mm. Repeat portosystemic gradient measurement was 14 mmHg. Large caliber varices filled . The stent was then dilated to 10 mm. There was persistent filling of the large caliber varices. At this point, a Davis catheter and hydrophilic guide wire were used to select the larger varices. A total of three varices were selected and embolized with metallic coils. Repeat angiography confirmed no persistent filling of those varices. Repeat angiography of the TIPS shunt confirmed patency, but a stenosis near the hepatic venous end. This was dilated to 10 mm. Repeat angiography from the portal vein revealed a widely patent stent and repeat pressures were measured at 19 mmHg portal and 13 mmHg systemic for a portosystemic gradient of 6 mmHg. At this point, catheters were removed a triple lumen left in place in the SVC. PROCEDURES PERFORMED: 1. TIPS creation. 2. Coil embolization gastric varices. 3. Triple lumen catheter placement. IMPRESSION: 1. TIPS SHUNT CREATION AS DESCRIBED WITH RESULTANT DECREASE IN PORTOSYSTEMIC GRADIENT FROM 17 mmHg TO 6 mmHg. 2. COIL EMBOLIZATION OF GASTRIC VARICES AS DESCRIBED. 3. TRIPLE LUMEN CATHETER PLACEMENT. |
|
|
|
|
|
RAD |
|
51391-1 |
|
RF.angio |
|
|
Both |
|
|
|
0 |
RFA Guided Portal v+Hepatic v TIPS place |
|
|
|
N |
|
Abd; Abdo; Abdomen+; Abdominal; Cardio; Cardiology; Document; Finding; Findings; Fluor; Fluoro; Fluoroscopy; Guid; Guide; Guided; Heart Disease; Hep v; Hep vein; Hepar; Imaging; Liver; Liver vein; Point in time; Portal v+Hepatic v; Portal+Hepatic v; PV; Rad; Radiology; Random; RFA; Shuntogm; Shuntogram; TIPS place; TIPSS; Ven; Venous |
2.64 |
2.22 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Jan 2016 Changed System from "Portal vein+Hepatic vein" to "Abdomen>Portal vein+Hepatic vein" to conform with LOINC/RadLex unified model; Method of "XR.fluor.angio" was changed to "RF.angio". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier.; Added "transjugular" as approach for the "placement" action per LOINC/RadLex unified model |
0 |
51392-9 |
Views |
Find |
Upper extremity.left>Wrist+Hand |
Pt |
Doc |
XR |
|
ACTIVE |
XR Wrist - left and Hand - left Views |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
51392-9 |
|
XR |
|
|
Both |
|
|
|
0 |
XR Wrist+Hand-L Views |
|
|
|
N |
|
Arm; Carpal bone; Carpal bones; Carpal bones and joint; Document; EXT; Extr-L; Films; Finding; Findings; Imaging; L; LT; LUE; MSK; Musculoskeletal; Ortho; Orthopedics; Plain Films; Point in time; Rad; RADIOLOGY; Random; UE; UE-L; Up; Upper extremity; Upper extremity joint; View; VWS; Wrist+Hand-L; Wrist-L; Xray; X-ray |
2.64 |
2.22 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Updated System from "Wrist.left+Hand.left" per LOINC/RadLex unified model |
0 |
51393-7 |
Esophageal manometry study |
Find |
Esophagus |
Stdy |
Doc |
Manometry |
|
ACTIVE |
Esophageal manometry study |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ENDO.GI |
|
51393-7 |
|
Manometry |
|
|
Both |
|
|
|
0 |
Manometry study |
|
|
|
N |
|
Document; Esophageal; Finding; Findings; Gastro; Gastroenterology; GI; GI.ENDOSCOPY; Studies; Study; Study report; Sutdies |
2.72 |
2.22 |
|
|
|
|
|
|
|
|
|
|
Release 2.72: COMPONENT: Update naming convention for studies.; SCALE_TYP: Modeling consistency for studies.; |
0 |
51394-5 |
Views |
Find |
Lower extremity.right>Ankle+Foot |
Pt |
Doc |
XR |
|
ACTIVE |
XR Ankle and Foot - right Views |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
51394-5 |
|
XR |
|
|
Both |
|
|
|
0 |
XR Ankle+Foot-R Views |
|
|
|
N |
|
Ankle+Foot-R; Ankle-R; Document; EXT; Extr-R; Films; Finding; Findings; Ft; Imaging; LE; Leg; LE-R; Low; Lower extremity; Lower extremity joint; MSK; Musculoskeletal; Ortho; Orthopedics; Plain Films; Point in time; R; Rad; RADIOLOGY; Random; RLE; RT; View; VWS; Xray; X-ray |
2.64 |
2.22 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Updated System from "Ankle.right+Foot.right" to conform with LOINC/RadLex unified model |
0 |
51395-2 |
Views |
Find |
Lower extremity.left>Ankle+Foot |
Pt |
Doc |
XR |
|
ACTIVE |
XR Ankle and Foot - left Views |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
51395-2 |
|
XR |
|
|
Both |
|
|
|
0 |
XR Ankle+Foot-L Views |
|
|
|
N |
|
Ankle+Foot-L; Ankle-L; Document; EXT; Extr-L; Films; Finding; Findings; Imaging; L; LE; Leg; LE-L; LLE; Low; Lower extremity; Lower extremity joint; LT; MSK; Musculoskeletal; Ortho; Orthopedics; Plain Films; Point in time; Rad; Radiology; Random; View; VWS; Xray; X-ray |
2.64 |
2.22 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Updated System from "Ankle.left+Foot.left" to conform with LOINC/RadLex unified model |
0 |
51396-0 |
Cells.CD65w/Cells |
NFr |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
CD65w cells/cells in Tissue |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51396-0 |
|
|
|
|
Observation |
|
|
|
0 |
CD65w Cells NFr Tiss |
|
|
|
N |
|
CD65w Cells; Cell; CELL MARKERS; Cellularity; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
51397-8 |
Cells.CD65w/Cells |
NFr |
CSF |
Pt |
Qn |
|
|
ACTIVE |
CD65w cells/cells in Cerebral spinal fluid |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51397-8 |
|
|
|
|
Observation |
|
|
|
0 |
CD65w Cells NFr CSF |
|
|
|
N |
|
CD65w Cells; Cell; CELL MARKERS; Cellularity; Cerebral spinal fluid; Cerebrospinal Fl; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
51398-6 |
Cells.CD65w/Cells |
NFr |
Bone mar |
Pt |
Qn |
|
|
ACTIVE |
CD65w cells/cells in Bone marrow |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51398-6 |
|
|
|
|
Observation |
|
|
|
0 |
CD65w Cells NFr Mar |
|
|
|
N |
|
BM; BON; Bone marrow; CD65w Cells; Cell; CELL MARKERS; Cellularity; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
51399-4 |
Cells.CD65w/Cells |
NFr |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
CD65w cells/cells in Body fluid |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51399-4 |
|
|
|
|
Observation |
|
|
|
0 |
CD65w Cells NFr Fld |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; CD65w Cells; Cell; CELL MARKERS; Cellularity; Fl; Fld; FLU; Fluid; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
514-0 |
Trimethoprim |
Titr |
Isolate+Ser |
Pt |
SemiQn |
SBT |
|
ACTIVE |
Trimethoprim [Susceptibility] by Serum bactericidal titer |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
ABXBACT |
|
514-0 |
|
SBT |
|
|
Observation |
|
|
|
0 |
Trimethoprim Titr SBT |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; c202; c242; C62; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Polytrim; Primsol; Proloprim; Random; Sequence based typing; Serum; SERUM BACTERICIDAL TITER; Serum killing test; SmQn; SR; Titer; Titered; Titre; TMP; Trimeth; Trimpex; Ttr |
2.75 |
1 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
5140-9 |
Echovirus 3 Ab.Neut |
Titr |
Ser |
Pt |
SemiQn |
Neut |
|
ACTIVE |
Echovirus 3 neutralizing antibody [Titer] in Serum by Neutralization test |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
5140-9 |
|
Neut |
|
|
Both |
|
|
|
0 |
ECV3 NAb Titr Ser Nt |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Conventional virus neutralization test; cVNT; Dilution factor; Dilution Factor (Titer); Echo; Echo virus; Echovirus type 3; ECV; ECV3; EV; ID; III; Infectious Disease; InfectiousDisease; Microbiology; NAb; NEUTRALIZATION; Neutralization test; NT; Point in time; Random; Serum; Serum virus neutralization; SmQn; SR; SVN; Titer; Titered; Titre; Ttr; Virus neutralization test; VNT |
2.75 |
1 |
|
|
|
|
|
|
|
{titer} |
|
|
Release 2.72: COMPONENT: Updated "Ab" to "Ab.Neut" since this test is detecting neutralizing antibodies.; |
0 |
51400-0 |
Cells.CD65w/Cells |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD65w cells/cells in Blood |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51400-0 |
|
|
|
|
Observation |
|
|
|
0 |
CD65w Cells NFr Bld |
|
|
|
N |
|
Blood; CD65w Cells; Cell; CELL MARKERS; Cellularity; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
51401-8 |
Cells.CD81/Cells |
NFr |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
CD81 cells/cells in Tissue |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51401-8 |
|
|
|
|
Observation |
|
|
|
0 |
CD81 Cells NFr Tiss |
|
|
|
N |
|
CD81 Cells; Cell; CELL MARKERS; Cellularity; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; TAPA-1; Tissue; Tissue, unspecified |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
51402-6 |
Cells.CD81/Cells |
NFr |
CSF |
Pt |
Qn |
|
|
ACTIVE |
CD81 cells/cells in Cerebral spinal fluid |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51402-6 |
|
|
|
|
Observation |
|
|
|
0 |
CD81 Cells NFr CSF |
|
|
|
N |
|
CD81 Cells; Cell; CELL MARKERS; Cellularity; Cerebral spinal fluid; Cerebrospinal Fl; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; TAPA-1 |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
51403-4 |
Cells.CD81/Cells |
NFr |
Bone mar |
Pt |
Qn |
|
|
ACTIVE |
CD81 cells/cells in Bone marrow |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51403-4 |
|
|
|
|
Observation |
|
|
|
0 |
CD81 Cells NFr Mar |
|
|
|
N |
|
BM; BON; Bone marrow; CD81 Cells; Cell; CELL MARKERS; Cellularity; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; TAPA-1 |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
51404-2 |
Cells.CD81/Cells |
NFr |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
CD81 cells/cells in Body fluid |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51404-2 |
|
|
|
|
Observation |
|
|
|
0 |
CD81 Cells NFr Fld |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; CD81 Cells; Cell; CELL MARKERS; Cellularity; Fl; Fld; FLU; Fluid; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; TAPA-1 |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
51405-9 |
Cells.CD81/Cells |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD81 cells/cells in Blood |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
51405-9 |
|
|
|
|
Observation |
|
|
|
0 |
CD81 Cells NFr Bld |
|
|
|
N |
|
Blood; CD81 Cells; Cell; CELL MARKERS; Cellularity; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; TAPA-1; WB; Whole blood |
2.79 |
2.22 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
51406-7 |
Immunoglobulin light chains.free |
MRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Immunoglobulin light chains.free [Mass/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
g/d |
|
|
|
|
|
|
CHEM |
|
51406-7 |
|
|
|
|
Both |
|
|
|
0 |
BJ Protein Free 24h Ur-mRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; Bence Jones protein; BJ Protein; BJ Protein Free; BJP; Chain; Chemistry; FLC; FR; Hematology; Heme; Immune globulin; Immuno; Immunoglob; Immunoglobin; Imunoglbon; Imunoglobn; Mass rate; mRate; Non-protein bound; QNT; Quan; Quant; Quantitative; UA; UR; Urn |
2.73 |
2.22 |
|
|
|
|
|
|
|
g/(24.h) |
|
|
|
0 |
51407-5 |
Streptococcus pneumoniae capsular polysaccharide Ab.IgG |
MCnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Streptococcus pneumoniae capsular polysaccharide IgG Ab [Mass/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
MICRO |
|
51407-5 |
|
IA |
|
|
Both |
|
|
|
0 |
S pneum CPS IgG Ser IA-mCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Capsule; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Level; Mass concentration; MEIA; Microbiology; Pneu; pneum; Pneumo; Pneumococ; Pneumococcal; Pneumococcal pneumonia; Pneumococcus; Pneumon; Pneumonia; Point in time; QNT; Quan; Quant; Quantitative; Random; S pneum CPS; S pneumo; S pneumoniae; Serum; Spn; SR; Strep; Strept; Streptococcus pneumoniae CPS; SUDS |
2.7 |
2.22 |
|
|
|
|
|
|
|
mg/L |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
51408-3 |
Streptococcus pneumoniae capsular polysaccharide Ab.IgG2 |
MCnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Streptococcus pneumoniae capsular polysaccharide IgG2 Ab [Mass/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
MICRO |
|
51408-3 |
|
IA |
|
|
Both |
|
|
|
0 |
S pneum CPS IgG2 Ser IA-mCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Capsule; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Infectious Disease; InfectiousDisease; Level; Mass concentration; MEIA; Microbiology; Pneu; pneum; Pneumo; Pneumococ; Pneumococcal; Pneumococcal pneumonia; Pneumococcus; Pneumon; Pneumonia; Point in time; QNT; Quan; Quant; Quantitative; Random; S pneum CPS; S pneumo; S pneumoniae; Serum; Spn; SR; Strep; Strept; Streptococcus pneumoniae CPS; SUDS |
2.7 |
2.22 |
|
|
|
|
|
|
|
mg/L |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
51409-1 |
Fosamprenavir+Ritonavir |
Susc |
Isolate |
Pt |
Ord |
Genotyping |
|
ACTIVE |
Fosamprenavir+Ritonavir [Susceptibility] by Genotype method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
51409-1 |
|
Genotyping |
|
|
Both |
|
|
|
0 |
Fosamprenavir+Ritonavir Islt Genotyp |
|
|
|
N |
|
908; ANTIBIOTIC SUSCEPTIBILITIES; AST; FPV; Genotype; Genotypic; GW433908; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Lexiva; Norvir; Ordinal; Point in time; QL; Qual; Qualitative; Random; RTV; Screen; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Telzir |
2.73 |
2.22 |
|
|
|
|
|
|
|
|
|
|
Corrected Scale from OrdQn to Ord because Genotyping does not produce a quantitative susceptibility result |
0 |
5141-7 |
Echovirus 3 Ab |
Titr |
Ser |
Pt |
SemiQn |
Comp fix |
|
ACTIVE |
Echovirus 3 Ab [Titer] in Serum by Complement fixation |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
5141-7 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
ECV3 Ab Titr Ser CF |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CF; Comp fixation; Compfix; Complement fixation; Dilution factor; Dilution Factor (Titer); Echo; Echo virus; Echovirus type 3; ECV; ECV3; EV; ID; III; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |